Pipeline
Indication
Asset
in-vitro PoC
in-vivo PoC
Lead Nomination
Lead Optimization
IND Enabling
Target Validation
FZ07- ADC
HNSCC*
Osteosarcoma
*Head and neck squamous cell carcinoma
FZ01 - mAb
FZ01
FZ01 monoclonal antibody (mAb) targets a secreted lysosomal enzyme present in the tumor microenvironment. The enzyme is a validated cancer target involved in lipid metabolism and essential for dormant cancer cell reactivation. FZ01 is the first-in-class biological metabolic inhibitor.
FZ01 is in development for clinical use as an adjuvant therapy in combination with standard-of-care chemotherapy or targeted therapy to extend time in remission.
Supporting in-vivo evidence:
FZ01 prevents tumor re-growth after chemotherapy.
FZ01 enhances the effect of cisplatin chemotherapy on tumor growth.
FZ01 is effective against both dividing and non-dividing cancer cells.
FZ07
FZ07 ADC is a receptor-specific antibody coupled with a cytotoxic payload. The antibody binds to the receptor expressed on the surface of dormant cancer cells. The receptor undergoes endocytosis and delivers the ADC to the lysosome where the payload is released.
FREZENT is interested in delivering a payload that blocks lipid metabolism in the lysosome, bringing a unique biology and first-in-class ADC modality for cancer therapy.
